Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction – Medical Marijuana Program Connection

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announced that it has received a unanimous positive recommendation from the Data Safety Monitoring Board (DSMB) to continue, without modifying the protocol, the phase 2b clinical study with AEF0117 for the treatment of cannabis addiction. A DSMB is a committee of independent expe

Source link